Log In
BCIQ
Print this Print this
 

NOV202

  Manage Alerts
Collapse Summary General Information
Company Noviga Research AB
DescriptionTubulin inhibitor and vascular disrupting agent
Molecular Target Tubulin
Mechanism of ActionTubulin inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer that is refractory to first-line therapies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today